PL2085388T3 - Nowa pochodna 1,2-dihydrochinoliny, zawierająca jako podstawniki podstawioną grupę fenyloamino-niższą alkilową oraz wprowadzoną przez ester grupę fenylową - Google Patents

Nowa pochodna 1,2-dihydrochinoliny, zawierająca jako podstawniki podstawioną grupę fenyloamino-niższą alkilową oraz wprowadzoną przez ester grupę fenylową

Info

Publication number
PL2085388T3
PL2085388T3 PL07831812T PL07831812T PL2085388T3 PL 2085388 T3 PL2085388 T3 PL 2085388T3 PL 07831812 T PL07831812 T PL 07831812T PL 07831812 T PL07831812 T PL 07831812T PL 2085388 T3 PL2085388 T3 PL 2085388T3
Authority
PL
Poland
Prior art keywords
substituents
ester
novel
lower alkyl
alkyl group
Prior art date
Application number
PL07831812T
Other languages
English (en)
Inventor
Mamoru Matsuda
Masato Nagatsuka
Toshiyuki Mori
Sachiko Kobayashi
Masatomo Kato
Miwa Takai
Original Assignee
Santen Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santen Pharmaceutical Co Ltd filed Critical Santen Pharmaceutical Co Ltd
Publication of PL2085388T3 publication Critical patent/PL2085388T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/04—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms
    • C07D215/06—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms having only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Addiction (AREA)
  • Vascular Medicine (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
PL07831812T 2006-11-14 2007-11-14 Nowa pochodna 1,2-dihydrochinoliny, zawierająca jako podstawniki podstawioną grupę fenyloamino-niższą alkilową oraz wprowadzoną przez ester grupę fenylową PL2085388T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2006307651 2006-11-14
EP07831812A EP2085388B1 (en) 2006-11-14 2007-11-14 Novel 1,2-dihydroquinoline derivative having substituted phenylamino lower alkyl group and ester-introduced phenyl group as substituents
PCT/JP2007/072082 WO2008059866A1 (en) 2006-11-14 2007-11-14 Novel 1,2-dihydroquinoline derivative having substituted phenylamino lower alkyl group and ester-introduced phenyl group as substituents

Publications (1)

Publication Number Publication Date
PL2085388T3 true PL2085388T3 (pl) 2013-01-31

Family

ID=39401671

Family Applications (3)

Application Number Title Priority Date Filing Date
PL07831812T PL2085388T3 (pl) 2006-11-14 2007-11-14 Nowa pochodna 1,2-dihydrochinoliny, zawierająca jako podstawniki podstawioną grupę fenyloamino-niższą alkilową oraz wprowadzoną przez ester grupę fenylową
PL07831813T PL2085389T3 (pl) 2006-11-14 2007-11-14 Pochodna 1,2-dihydrochinoliny, zawierająca jako podstawniki (podstawioną fenylem lub podstawioną grupą heterocykliczną) grupę karbonyloksy-niższą alkilową oraz wprowadzoną przez ester grupę fenylową
PL07831811T PL2085387T3 (pl) 2006-11-14 2007-11-14 Nowe pochodne 1,2-dihydrochinoliny zawierające jako podstawniki fenylochalkogeno-podstawioną niższą grupę alkilową oraz wprowadzoną przez ester grupę fenylową

Family Applications After (2)

Application Number Title Priority Date Filing Date
PL07831813T PL2085389T3 (pl) 2006-11-14 2007-11-14 Pochodna 1,2-dihydrochinoliny, zawierająca jako podstawniki (podstawioną fenylem lub podstawioną grupą heterocykliczną) grupę karbonyloksy-niższą alkilową oraz wprowadzoną przez ester grupę fenylową
PL07831811T PL2085387T3 (pl) 2006-11-14 2007-11-14 Nowe pochodne 1,2-dihydrochinoliny zawierające jako podstawniki fenylochalkogeno-podstawioną niższą grupę alkilową oraz wprowadzoną przez ester grupę fenylową

Country Status (12)

Country Link
US (6) US8008498B2 (pl)
EP (3) EP2085388B1 (pl)
JP (3) JP4817020B2 (pl)
KR (3) KR20090086539A (pl)
CN (4) CN101535266A (pl)
CA (3) CA2668592C (pl)
ES (3) ES2391865T3 (pl)
HK (1) HK1208868A1 (pl)
NO (1) NO342905B1 (pl)
PL (3) PL2085388T3 (pl)
RU (1) RU2485104C2 (pl)
WO (3) WO2008059866A1 (pl)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1944290B1 (en) 2005-09-14 2013-12-04 Santen Pharmaceutical Co., Ltd. Novel 1-2-dihydroquinoline derivative having glucocorticoid receptor binding activity
PL1995242T3 (pl) 2006-03-14 2013-03-29 Santen Pharmaceutical Co Ltd Nowa pochodna 1,2,3,4-tetrahydrochinoksaliny, mająca aktywność wiążącą receptor glukokortykoidowy
PL2085388T3 (pl) 2006-11-14 2013-01-31 Santen Pharmaceutical Co Ltd Nowa pochodna 1,2-dihydrochinoliny, zawierająca jako podstawniki podstawioną grupę fenyloamino-niższą alkilową oraz wprowadzoną przez ester grupę fenylową
WO2008146871A1 (ja) * 2007-05-29 2008-12-04 Santen Pharmaceutical Co., Ltd. グルココルチコイド受容体結合活性を有する、スルホン酸エステル又はスルホン酸アミド構造を導入したフェニル基を置換基として有する新規１，２，３，４－テトラヒドロキノキサリン誘導体
WO2009139361A1 (ja) * 2008-05-12 2009-11-19 参天製薬株式会社 置換オキシ基を有する２，２，４－トリメチル－６－フェニル－１，２－ジヒドロキノリン誘導体からなるグルココルチコイド受容体アゴニスト
KR20110053467A (ko) * 2008-09-12 2011-05-23 산텐 세이야꾸 가부시키가이샤 술폰산에스테르 구조를 도입한 페닐기를 치환기로서 갖는 신규 1,2,3,4-테트라히드로퀴녹살린 유도체를 포함하는 글루코코르티코이드 수용체 작용제
MY155463A (en) 2008-09-30 2015-10-15 Hitachi Chemical Co Ltd Coating agent, substrate for mounting optical semiconductor element using same, and optical semiconductor device
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
KR20140002735A (ko) * 2011-02-09 2014-01-08 산텐 세이야꾸 가부시키가이샤 3-히드록시-6H-벤조[c]크로멘-6-온 유도체 및 그 제조 방법
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US20140371459A1 (en) * 2012-01-20 2014-12-18 Santen Pharmaceutical Co., Ltd. Industrial process for preparation of 1,2-dihydroquinoline derivative or a salt thereof, and intermediate for preparation thereof
TW201336526A (zh) 2012-01-31 2013-09-16 參天製藥股份有限公司 非水性液體組成物
JP2014139161A (ja) * 2012-12-20 2014-07-31 Santen Pharmaceut Co Ltd １，２−ジヒドロキノリン合成中間体の製造方法
TW201609145A (zh) 2013-12-25 2016-03-16 參天製藥股份有限公司 注射劑及形成緩釋（ｄｅｐｏｔ）之方法
US11433090B2 (en) 2017-06-16 2022-09-06 The Doshisha mTOR-inhibitor-containing medicine for treating or preventing ophthalmic symptoms, disorders, or diseases, and application thereof
EP3639855A4 (en) 2017-06-16 2021-03-17 The Doshisha COMPOUNDS HAVING CASPASE INHIBITORING ACTIVITY, PHARMACEUTICAL AGENT CONTAINING THEM FOR THE TREATMENT OR PREVENTION OF SYMPTOMS, DISORDERS OR DISEASES OF CORNEAL ENDOTHELIUM, AND APPLICATION OF SUCH PHARMACEUTICAL AGENT

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6696459B1 (en) 1994-12-22 2004-02-24 Ligand Pharmaceuticals Inc. Steroid receptor modulator compounds and methods
CZ176197A3 (cs) 1994-12-22 1998-09-16 Ligand Pharmaceuticals Incorporated Modulátory steroidových receptorů a způsoby jejich přípravy a použití
US5693647A (en) 1994-12-22 1997-12-02 Ligand Pharmaceuticals Incorporated Steroid receptor modulator compounds and methods
US6372073B1 (en) * 1999-08-11 2002-04-16 Southpac Trust International Inc. Process for producing holographic material
SK5212003A3 (en) * 2000-10-02 2004-03-02 Janssen Pharmaceutica Nv Metabotropic glutamate receptor antagonists
DE60113032T2 (de) 2000-10-30 2006-07-06 Pfizer Products Inc., Groton Glukokortikoidrezeptor-Modulatoren
PL373763A1 (pl) 2002-04-30 2005-09-19 Ucb, S.A. Pochodne 2,6-chinolinylowe i 2,6-naftylowe, sposoby ich wytwarzania i ich zastosowanie jako inhibitorów VLA-4
CA2496175A1 (en) 2002-08-21 2004-03-04 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted hihydroquinolines as glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
KR20070056060A (ko) 2004-07-14 2007-05-31 리간드 파마슈티칼스 인코포레이티드 세포내 수용체 조절화합물 및 방법
EP1944290B1 (en) * 2005-09-14 2013-12-04 Santen Pharmaceutical Co., Ltd. Novel 1-2-dihydroquinoline derivative having glucocorticoid receptor binding activity
JP4825636B2 (ja) * 2005-09-14 2011-11-30 参天製薬株式会社 グルココルチコイド受容体結合活性を有する新規１，２−ジヒドロキノリン誘導体
PL2085388T3 (pl) 2006-11-14 2013-01-31 Santen Pharmaceutical Co Ltd Nowa pochodna 1,2-dihydrochinoliny, zawierająca jako podstawniki podstawioną grupę fenyloamino-niższą alkilową oraz wprowadzoną przez ester grupę fenylową
WO2008111632A1 (ja) * 2007-03-13 2008-09-18 Santen Pharmaceutical Co., Ltd. ２，２，４－トリメチル－６－フェニル－１，２－ジヒドロキノリン誘導体からなるグルココルチコイド受容体アゴニスト
CN101959468B (zh) * 2008-03-06 2012-09-05 斯恩蒂斯有限公司 小面干涉螺钉
WO2009139361A1 (ja) * 2008-05-12 2009-11-19 参天製薬株式会社 置換オキシ基を有する２，２，４－トリメチル－６－フェニル－１，２－ジヒドロキノリン誘導体からなるグルココルチコイド受容体アゴニスト

Also Published As

Publication number Publication date
EP2085389B1 (en) 2012-09-26
CN101605762A (zh) 2009-12-16
KR20090086069A (ko) 2009-08-10
JP2008143891A (ja) 2008-06-26
EP2085389A1 (en) 2009-08-05
JP4817020B2 (ja) 2011-11-16
EP2085388A4 (en) 2010-12-15
KR101475534B1 (ko) 2014-12-22
HK1208868A1 (en) 2016-03-18
EP2085387B1 (en) 2013-04-10
RU2485104C2 (ru) 2013-06-20
US8008497B2 (en) 2011-08-30
JP2008143889A (ja) 2008-06-26
WO2008059866A1 (en) 2008-05-22
US8008498B2 (en) 2011-08-30
CA2669607A1 (en) 2008-05-22
US20090298827A1 (en) 2009-12-03
US20110263600A1 (en) 2011-10-27
WO2008059867A1 (en) 2008-05-22
US20110275632A1 (en) 2011-11-10
US20100056504A1 (en) 2010-03-04
PL2085387T3 (pl) 2013-09-30
ES2391865T3 (es) 2012-11-30
ES2416289T3 (es) 2013-07-31
US20110275620A1 (en) 2011-11-10
CA2668592C (en) 2016-04-19
JP4898635B2 (ja) 2012-03-21
US8008496B2 (en) 2011-08-30
CA2668596A1 (en) 2008-05-22
CN101535266A (zh) 2009-09-16
US8440660B2 (en) 2013-05-14
EP2085388A1 (en) 2009-08-05
ES2391910T3 (es) 2012-12-03
EP2085389A4 (en) 2010-12-15
CN104672130A (zh) 2015-06-03
NO20092104L (no) 2009-05-28
EP2085387A1 (en) 2009-08-05
RU2009122375A (ru) 2010-12-20
JP4969417B2 (ja) 2012-07-04
US8563551B2 (en) 2013-10-22
NO342905B1 (no) 2018-08-27
CA2668592A1 (en) 2008-05-22
WO2008059865A1 (en) 2008-05-22
US8580784B2 (en) 2013-11-12
PL2085389T3 (pl) 2013-02-28
EP2085387A4 (en) 2010-12-15
CN101535267A (zh) 2009-09-16
JP2008143890A (ja) 2008-06-26
US20090298826A1 (en) 2009-12-03
EP2085388B1 (en) 2012-09-05
KR20090086070A (ko) 2009-08-10
KR20090086539A (ko) 2009-08-13

Similar Documents

Publication Publication Date Title
EP2085388A4 (en) NEW 1,2-DIHYDROCHINOLINE DERIVATIVE WITH SUBSTITUTED PHENYLAMINOENE ALKYL GROUP AND PHENYL GROUP INTRODUCED BY AN ESTER AS SUBSTITUENTS
ZA200710172B (en) Cyclic amine derivative having substituted alkyl group
IL192102A0 (en) 1,3-oxazolidin-2-one derivatives useful as cetp inhibitors
IL189141A0 (en) Quinoline derivatives as antibacterial agents
IL189142A0 (en) Quinoline derivatives as antibacterial agents
TWI369353B (en) Novel compound having 4-pyridylalkylthio group as substituent
AP2007004264A0 (en) Quinoline derivatives as antibacterial agents
IL188395A0 (en) Quinoline derivatives as antibacterial agents
ZA200801106B (en) Quinoline derivatives as antibacterial agents
IL188393A0 (en) Quinoline derivatives as antibacterial agents
IL188394A0 (en) Quinoline derivatives as antibacterial agents
ZA200704309B (en) Benzene compound having 2 or more substituents
IL178734A0 (en) Novel alkyl substituted piperazine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
ZA200609067B (en) Novel alkyl substituted piperazine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
GB0508820D0 (en) Lubricating compositions
ZA200609519B (en) Benzylidene-ß-Dicarbonyl compounds as novel UV-absorbers
PL375805A1 (pl) Pochodne chinoliny wykazujące aktywność jako fungicydy oraz ich stosowanie
GB0514423D0 (en) Novel compositions and compounds
ZA200710698B (en) Quinoline derivatives as antibacterial agents